ExiTron™ nano 6000 is a nanoparticulate CT contrast agent designed for preclinical liver imaging and detection of hepatic tumors and metastases. It is rapidly phagocytosed by Kupffer cells, providing sustained hepatic enhancement for several weeks. This profile enables detailed visualization of liver morphology and lesion progression in small animal models. Procuring the agent through an authorized distributor ensures regulatory compliant shipping, local technical support, and consistent supply for longitudinal studies.
Conventional CT contrast agents often provide transient liver enhancement, limiting assessment of chronic or progressive hepatic conditions. ExiTron™ nano 6000 addresses this limitation through prolonged retention in healthy liver tissue, allowing repeated imaging sessions without additional contrast administration. The agent also provides strong enhancement of spleen tissue, supporting comprehensive assessment of the reticuloendothelial system.
Following administration, ExiTron™ nano 6000 accumulates in liver parenchyma, producing high contrast between healthy tissue and surrounding structures. This contrast facilitates clear identification of liver tumors and metastatic lesions, supports quantitative measurement of tumor burden, and enables monitoring of morphological changes over time. The low injection volume and favorable cardiovascular tolerability make the agent suitable for animals with limited physiological reserve.
ExiTron™ nano 6000 is applied in micro CT studies targeting liver morphology, tumor detection, metastasis tracking, and longitudinal disease progression. Its long hepatic retention allows researchers to conduct repeated imaging from hours to weeks post injection, supporting robust experimental workflows in oncology, hepatology, and pharmacological studies.
ExiTron™ nano 6000 consists of nanoparticles engineered for liver uptake and imaging stability. The mean hydrodynamic diameter is approximately 110 nanometers. Undiluted X ray attenuation reaches approximately 6000 Hounsfield units, providing strong contrast for preclinical liver imaging.
Imaging studies demonstrate clear opacification of liver lobes and metastases in murine models following a single injection. Longitudinal monitoring confirms sustained enhancement suitable for quantitative assessment of lesion progression and therapeutic response.
ExiTron™ nano 6000 has been validated in peer reviewed studies covering liver imaging, tumor and metastasis detection, and longitudinal assessment of hepatic injury in small animal models.
ExiTron™ nano 6000 is available in formats suitable for single or repeated study series, including options containing one set of five injections or five sets of five injections. Ordering through an authorized distributor provides access to local support, institutional purchasing assistance, and custom quotations.
Supporting resources include a detailed product data sheet describing formulation properties, recommended usage, and imaging guidance for liver and hepatic lesion studies.
Authorized distributor of Viscover products by Nanopet Pharma GmbH. This page contains original distributor specific content intended to support preclinical liver imaging and hepatic research.
Price range: USD $493 through USD $2,250
